Biliary tract tumor
Conditions
Interventions
1:apatinib + S-1
Sponsors
Shanghai Dongfang Department of Hepatobiliary Surgery Hospital precision Medicine Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) pathology or cytology is diagnosed as intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma; (2) according to the RECIST standard (see Appendix 1), measurable assessment can be made; (3) aged from 18 to 75 years; (4) WHO/ECOG physical strength score (see Appendix 2) reached 0-2; (5) there were at least 3 cycles of GP chemotherapy before; (6) enough bone marrow hematopoietic reserve (white blood cell count > 3 x 10^9/L, platelet count > 100 x10^9/L); (7) adequate liver bilirubin (equal to or less than 1.5 times the upper limit of normal (ULN); (8) adequate renal reserve (creatinine clearance > 60 ml/min; creatinine <120 mu mol/L). (9) no heart failure and uncontrolled chest pain. No myocardial infarction occurred within 12 months before the start of the study; (10) the letter of informed consent was signed.
Exclusion criteria
Exclusion criteria: (1) in the 3 years before the start of the study, there were two malignant tumors or other tumors accompanied by metastasis of brain or meninges; (2) there are contraindications related to the use of apatinib, such as severe hypertension, high bleeding risk, and severe nephrotic syndrome; (3) with chronic diarrhea or colitis or inflammatory conditions, effects of systemic administration of untreated good occlusion or sub block; (4) infection activity or other serious infections that may hinder patients from receiving planned treatment. For example, long term uncontrolled destruction of biliary tract bacterial cholangitis; (5) cardiac insufficiency, unstable angina pectoris, congestive heart failure, acute myocardial infarction and serious uncontrollable arrhythmia within the first 6 months of the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate; | — |
Countries
China
Contacts
Public ContactYuan Zhengang
Shanghai Orient Department of Hepatobiliary Surgery Hospital
Outcome results
None listed